BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akizawa T, Kurita N, Mizobuchi M, Fukagawa M, Onishi Y, Yamaguchi T, Ellis AR, Fukuma S, Alan Brookhart M, Hasegawa T, Kurokawa K, Fukuhara S. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 2016;6:19612. [PMID: 27071541 DOI: 10.1038/srep19612] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Rroji M, Spasovski G. Calcimimetics versus parathyroidectomy: What is preferable? Int Urol Nephrol 2018;50:1271-5. [DOI: 10.1007/s11255-018-1838-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Donthireddy SNR, Mathoor Illam P, Rit A. Ruthenium(II) Complexes of Heteroditopic N-Heterocyclic Carbene Ligands: Efficient Catalysts for C–N Bond Formation via a Hydrogen-Borrowing Strategy under Solvent-Free Conditions. Inorg Chem 2020;59:1835-47. [DOI: 10.1021/acs.inorgchem.9b03049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 9.5] [Reference Citation Analysis]
3 Wong CM, Peterson MB, Pernik I, Mcburney RT, Messerle BA. Highly Efficient Rh(I) Homo- and Heterogeneous Catalysts for C–N Couplings via Hydrogen Borrowing. Inorg Chem 2017;56:14682-7. [DOI: 10.1021/acs.inorgchem.7b02586] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mizobuchi M, Ogata H, Koiwa F. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment. Ther Apher Dial 2019;23:309-18. [PMID: 30411503 DOI: 10.1111/1744-9987.12772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
5 Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clin Drug Investig 2018;38:945-54. [PMID: 30168004 DOI: 10.1007/s40261-018-0687-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
6 Fukuma S, Fukuhara S, Shimizu S, Akizawa T, Fukagawa M. Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study. Sci Rep 2019;9:11301. [PMID: 31383933 DOI: 10.1038/s41598-019-47852-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Pibiri I, Beneduci A, Carraro M, Causin V, Casella G, Corrente GA, Chidichimo G, Pace A, Riccobono A, Saielli G. Mesomorphic and electrooptical properties of viologens based on non-symmetric alkyl/polyfluoroalkyl functionalization and on an oxadiazolyl-extended bent core. J Mater Chem C 2019;7:7974-83. [DOI: 10.1039/c9tc01697j] [Cited by in Crossref: 19] [Article Influence: 6.3] [Reference Citation Analysis]
8 Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Research on kidney and mineral metabolism in Japan: past, present, and future. Clin Exp Nephrol 2017;21:4-8. [DOI: 10.1007/s10157-016-1366-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial 2020;24:248-57. [PMID: 31486206 DOI: 10.1111/1744-9987.13434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Hung KC, Chang JF, Hsu YH, Hsieh CY, Wu MS, Wu MY, Chiu IJ, Syu RS, Wang TM, Wu CC, Hung LY, Zheng CM, Lu KC. Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease. Int J Mol Sci 2020;21:E8712. [PMID: 33218086 DOI: 10.3390/ijms21228712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clin Pharmacol 2018;10:101-11. [PMID: 30254496 DOI: 10.2147/CPAA.S171044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
12 Chaudhuri S, Long A, Zhang H, Monaghan C, Larkin JW, Kotanko P, Kalaskar S, Kooman JP, van der Sande FM, Maddux FW, Usvyat LA. Artificial intelligence enabled applications in kidney disease. Semin Dial 2021;34:5-16. [PMID: 32924202 DOI: 10.1111/sdi.12915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Zhuo L, Zhang L, Peng L, Yang Y, Lu H, Chen D, Li W, Yu M. Microwave ablation of hyperplastic parathyroid glands is a treatment option for end-stage renal disease patients ineligible for surgical resection. International Journal of Hyperthermia 2019;36:29-35. [DOI: 10.1080/02656736.2018.1528392] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
14 Tunbridge MJ, Jardine AG. Atherosclerotic Vascular Disease Associated with Chronic Kidney Disease. Cardiol Clin 2021;39:403-14. [PMID: 34247753 DOI: 10.1016/j.ccl.2021.04.011] [Reference Citation Analysis]
15 Saielli G. Computational Spectroscopy of Ionic Liquids for Bulk Structure Elucidation. Adv Theory Simul 2018;1:1800084. [DOI: 10.1002/adts.201800084] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
16 Hamano T, Sakaguchi Y, Fujii N, Isaka Y. Clinical features of CKD-MBD in Japan: cohort studies and registry. Clin Exp Nephrol 2017;21:9-20. [PMID: 27942882 DOI: 10.1007/s10157-016-1367-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Asada S, Yoshida K, Fukuma S, Nomura T, Wada M, Onishi Y, Kurita N, Fukagawa M, Fukuhara S, Akizawa T. Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study. PLoS One 2019;14:e0216399. [PMID: 31141505 DOI: 10.1371/journal.pone.0216399] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Matsuura R, Hidaka S, Ohtake T, Mochida Y, Ishioka K, Maesato K, Oka M, Moriya H, Kobayashi S. Intradialytic hypotension is an important risk factor for critical limb ischemia in patients on hemodialysis. BMC Nephrol 2019;20:473. [PMID: 31856757 DOI: 10.1186/s12882-019-1662-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Warady BA, Ng E, Bloss L, Mo M, Schaefer F, Bacchetta J. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol 2020;35:1679-97. [PMID: 32367309 DOI: 10.1007/s00467-020-04516-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Hamano N, Komaba H, Fukagawa M. Etelcalcetide for the treatment of secondary hyperparathyroidism. Expert Opinion on Pharmacotherapy 2017;18:529-34. [DOI: 10.1080/14656566.2017.1303482] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
21 Okada M, Tominaga Y, Ichimori T, Tomosugi T, Hiramitsu T, Tsuzuki T. Surgical outcomes of parathyroidectomy for secondary hyperparathyroidism resistant to calcimimetic treatment: A retrospective single-center cohort study. Ther Apher Dial 2021;25:188-96. [PMID: 32592622 DOI: 10.1111/1744-9987.13553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hamano N, Endo Y, Kawata T, Fukagawa M. Development of evocalcet for unmet needs among calcimimetic agents. Expert Rev Endocrinol Metab 2020;15:299-310. [PMID: 32552012 DOI: 10.1080/17446651.2020.1780911] [Reference Citation Analysis]
23 Pérez-Ricart A, Galicia-Basart M, Comas-Sugrañes D, Cruzado-Garrit JM, Segarra-Medrano A, Montoro-Ronsano JB. Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism. Kidney Res Clin Pract 2019;38:229-38. [PMID: 31022778 DOI: 10.23876/j.krcp.18.0088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
24 Wong CM, Mcburney RT, Binding SC, Peterson MB, Gonçales VR, Gooding JJ, Messerle BA. Iridium( iii ) homo- and heterogeneous catalysed hydrogen borrowing C–N bond formation. Green Chem 2017;19:3142-51. [DOI: 10.1039/c7gc01007a] [Cited by in Crossref: 28] [Article Influence: 5.6] [Reference Citation Analysis]
25 Kato C, Fujii N, Miyakoshi C, Asada S, Onishi Y, Fukuma S, Nomura T, Wada M, Fukagawa M, Fukuhara S, Akizawa T. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism. BMC Nephrol 2020;21:432. [PMID: 33045994 DOI: 10.1186/s12882-020-02088-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Hamano T. Mineral and bone disorders in conventional hemodialysis: Challenges and solutions. Semin Dial 2018;31:592-8. [PMID: 29900589 DOI: 10.1111/sdi.12729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
27 Pereira L, Meng C, Marques D, Frazão JM. Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J 2018;11:80-8. [PMID: 29423207 DOI: 10.1093/ckj/sfx125] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
28 Fukagawa M, Komaba H. Chronic Kidney Disease-Mineral and Bone Disorder in Asia. Kidney Dis (Basel) 2017;3:1-7. [PMID: 28785558 DOI: 10.1159/000470909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. Sci Rep 2019;9:6410. [PMID: 31015494 DOI: 10.1038/s41598-019-42017-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
30 Hoshino J. Introduction to clinical research based on modern epidemiology. Clin Exp Nephrol 2020;24:491-9. [PMID: 32212004 DOI: 10.1007/s10157-020-01870-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Fukagawa M, Shimazaki R, Akizawa T. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney International 2018;94:818-25. [DOI: 10.1016/j.kint.2018.05.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]